Myocardial protection in heart transplantation using blood cardioplegia: 12-year outcome of a prospective randomized trial

Use of blood cardioplegia is safe and results in comparable survival and prevalence of adverse events late after HTx. The trend towards greater freedom from chronic rejection and more limited extent of coronary artery disease in grafts protected with blood cardioplegia awaits confirmation.